ABT-239 is a histamine H3 receptor antagonist [52] and transient vanilloid receptor type 1 (TRPV1) antagonist proposed for the treatment of schizophrenia and attention-deficit/hyperactivity disorder (ADHD) [53]. This evidence concerns the gene HRH3 and schizophrenia.